Journal article
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma
American journal of hematology, Vol.86(12), pp.998-1000
12/2011
DOI: 10.1002/ajh.22168
PMCID: PMC3588858
PMID: 22006790
Abstract
The serum free light chain (FLC) assay quantitates free immunoglobulin kappa and lambda light chains, which has prognostic value in plasma cell dyscrasias. However, there is limited data on serum FLC in lymphoid malignancies. We analyzed the association of pretreatment FLC with event-free survival (EFS) and overall survival (OS) in 100 patients with Hodgkin lymphoma (HL). Elevated polyclonal FLC were present in 30% of patients; these patients had an inferior EFS (HR = 4.84; 95% CI: 1.84–12.7) and OS (HR = 8.87; 95% CI: 2.35–33.52) compared to patients with normal FLC. Further studies of FLC in HL are warranted.
Details
- Title: Subtitle
- Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma
- Creators
- Carrie A Thompson - Division of Hematology, Mayo Clinic, Rochester, MN 55905Matthew J Maurer - Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905James R Cerhan - Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905Jerry A Katzmann - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905Stephen M Ansell - Division of Hematology, Mayo Clinic, Rochester, MN 55905Thomas M Habermann - Division of Hematology, Mayo Clinic, Rochester, MN 55905William R Macon - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905George J Weiner - Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, IowaBrian K Link - Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, IowaThomas E Witzig - Division of Hematology, Mayo Clinic, Rochester, MN 55905
- Resource Type
- Journal article
- Publication Details
- American journal of hematology, Vol.86(12), pp.998-1000
- DOI
- 10.1002/ajh.22168
- PMID
- 22006790
- PMCID
- PMC3588858
- ISSN
- 0361-8609
- eISSN
- 1096-8652
- Grant note
- P50 CA097274 || CA / National Cancer Institute : NCI
- Language
- English
- Date published
- 12/2011
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984094333502771
Metrics
12 Record Views